Toxicology and immunotoxicology of mercury: a comparative review in fish and humans.

This review addresses an important area of environmental and mammalian toxicology by evaluating and comparing mercury-induced effects upon the immune responses of two evolutionarily divergent yet immunologically-related species. The mechanisms of mercury toxicology and immunotoxicology are described herein, including supporting data from the following: sources of exposure; bioavailability and biodistribution; metabolism; and laboratory and field investigations. Based upon the studies presented, the relative sensitivities of fish and human immune cells to mercury exposure are compared and contrasted with regard to mercury's ability to stimulate and/or suppress host immunocompetence. In addition, results from immune assays are compared to mercury tissue burdens, as well as to toxicological threshold level estimates. Such comparisons may help to resolve gaps in our knowledge regarding sensitivity of immunological assays, standardization of immunotoxicological techniques between species, and the extent to which the vertebrate immune system possesses functional reserve and redundancy in response to xenobiotics. A review of this type begins to provide support for the potential usefulness of fish immune cells to serve as indicators for human immunotoxicology risk assessment. Analysis of the reviewed studies supports the following conclusions in both lower and higher vertebrates: a threshold for mercury-induced immunotoxicological effects is likely; multiple exposure scenarios involving high and/or chronic exposures leading to increased body burdens are linked to increased risk of immunomodulation; and highly exposed and/or susceptible subpopulations are at greater risk of toxicological impact.

Acute and chronic life cycle toxicity of acenaphthene and 2,4,6-trichlorophenol to the midge Paratanytarsus parthenogeneticus (Diptera: Chironomidae).

The acute and life cycle toxicities of acenaphthene and 2,4,6-trichlorophenol (2,4,6-TCP) were evaluated using the parthenogenic dipteran larva, Paratanytarsus parthenogeneticus, of the family Chironomidae. Static 48 h acute toxicity tests employed third instar larvae, and the flow-through 20-day life cycle tests were initiated with eggs. No acute lethal effect was observed in the saturated concentration (2.1 mg/l) of acenaphthene in water, and the median lethal concentration of 2,4,6-TCP was approximately 40 mg/l. In the life cycle toxicity test with acenaphthene, hatchability of the midge was affected by 50% at an exposure concentration of approximately 0.17 mg/l. The median effective concentration for larval, pupal and adult development was found between 0.06 and 0.07 mg/l, respectively, and these were significantly lower than the effective concentration for hatching success. With regard to 2,4,6-TCP toxicity, the median effective concentration for midge hatchability was 4.23 mg/l. The larval development, pupal formation and adult emergence, however were impeded at 1.60, 1.46 and 1.33 mg/l, respectively. Each level was noticeably lower than the median effective concentration for hatchability. The concentrations for each compound that interfered with the development to fourth instar, pupa and adult were not significantly different. These results indicate that larval developments after hatching were the most sensitive stages and affected the success of midge growth.

Actin cytoskeletal function is spared, but apoptosis is increased, in WAS patient hematopoietic cells.

Mutations in the Wiskott-Aldrich syndrome protein (WASP) have been hypothesized to cause defective actin cytoskeletal function. This resultant dysfunction of the actin cytoskeleton has been implicated in the pathogenesis of Wiskott-Aldrich syndrome (WAS). In contrast, it was found that stimulated actin polymerization is kinetically normal in the hematopoietic lineages affected in WAS. It was also found that the actin cytoskeleton in WAS platelets is capable of producing the hallmark cytoarchitectural features associated with activation. Further analysis revealed accelerated cell death in WAS lymphocytes as evidenced by increased caspase-3 activity. This increased activity resulted in accelerated apoptosis of these cells. CD95 expression was also increased in these cells, suggesting an up-regulation in the FAS pathway in WAS lymphocytes. Additionally, inhibition of actin polymerization in lymphocytes using cytochalasin B did not accelerate apoptosis in these cells. This suggests that the accelerated apoptosis observed in WAS lymphocytes was not secondary to an underlying defect in actin polymerization caused by mutation of the WAS gene. These data indicate that WASP does not play a universal role in signaling actin polymerization, but does play a role in delaying cell death. Therefore, the principal consequence of mutations in the WAS gene is to accelerate lymphocyte apoptosis, potentially through up-regulation of the FAS-mediated cell death pathway. This accelerated apoptosis may ultimately give rise to the clinical manifestations observed in WAS. (Blood. 2000;95:1283-1292)